
Sanofi Genzyme has presented 10-year follow-up data on Lemtrada (alemtuzumab) which points to its efficacy in patients with relapsing-remitting multiple …
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations

